Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas

Journal of Human Genetics

Volumn 58, Issue 7, 2013, Pages 428-433

  Asada, Kiyoshi ^a   Abe, Masanobu ^a   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

CIMP; Neuroblastoma; Poor prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ISOTRETINOIN;

ADRENERGIC SYSTEM; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD CANCER; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; ESOPHAGEAL ADENOCARCINOMA; GAIN OF FUNCTION MUTATION; GENE DOSAGE; GENE EXPRESSION; GENE THERAPY; GENETIC SCREENING; GLIOBLASTOMA; HISTONE MODIFICATION; HUMAN; JAPANESE; LEUKEMIA; MICROSATELLITE INSTABILITY; NEUROBLASTOMA; ONCOGENE; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLOIDY; PROMOTER REGION; REVIEW; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; GENETIC THERAPY; HUMANS; NEUROBLASTOMA; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84880879970     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2013.64     Document Type: Review

References (50)

1. Church, T. R., Wandell, M., Lofton-Day, C., Mongin, S. J., Burger, M., Payne, S. R. et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut in press (2013
2. Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005
3. Van Neste, L., Herman, J. G., Otto, G., Bigley, J. W., Epstein, J. I. & Van Criekinge, W. The epigenetic promise for prostate cancer diagnosis. Prostate 72, 1248-1261 (2011
4. Teodoridis, J. M., Hardie, C. & Brown, R. CpG island methylator phenotype (CIMP) in cancer: Causes and implications. Cancer Lett. 268, 177-186 (2008
5. Cowan, L. A., Talwar, S., Yang, A. S. & Will, D. N. A. Methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2, 71-86 (2010
6. Foulks, J. M., Parnell, K. M., Nix, R. N., Chau, S., Swierczek, K., Saunders, M. et al. Epigenetic drug discovery: Targeting DNA methyltransferases. J. Biomol. Screen. 17, 2-17 (2012
7. Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced nonsmall cell lung cancer. Cancer Discov. 1, 598-607 (2011
8. Abe, M., Watanabe, N., McDonell, N., Takato, T., Ohira, M., Nakagawara, A. et al. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 74, 50-60 (2008
9. Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y. et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72, 2197-2205 (2012
10. Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B. & Issa, J. P. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681-8686 (1999
11. Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90-96 (2009
12. Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y. et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104, 18654-18659 (2007
13. Yagi, K., Akagi, K., Hayashi, H., Nagae, G., Tsuji, S., Isagawa, T. et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 16, 21-33 (2010
14. Suzuki, H., Igarashi, S., Nojima, M., Maruyama, R., Yamamoto, E., Kai, M. et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 31, 342-349 (2010
15. Hinoue, T., Weisenberger, D. J., Pan, F., Campan, M., Kim, M., Young, J. et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 4, e8357 (2009
16. Kim, H., Kim, Y. H., Kim, S. E., Kim, N. G. & Noh, S. H. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J. Pathol. 200, 23-31 (2003
17. Toyota, M., Ahuja, N., Suzuki, H., Itoh, F., Ohe-Toyota, M., Imai, K. et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59, 5438-5442 (1999
18. Marsit, C. J., Houseman, E. A., Christensen, B. C., Eddy, K., Bueno, R., Sugarbaker, D. J. et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res. 66, 10621-10629 (2006
19. Shen, L., Ahuja, N., Shen, Y., Habib, N. A., Toyota, M., Rashid, A. et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl Cancer Inst. 94, 755-761 (2002
20. Strathdee, G., Appleton, K., Illand, M., Millan, D. W., Sargent, J., Paul, J. et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 158, 1121-1127 (2001
21. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J. A., Navarro, G., Calasanz, M. J. et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin. Cancer Res. 12, 4845-4850 (2006
22. Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zochbauer-Muller, S. et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61, 8659-8663 (2001
23. Brock, M. V., Gou, M., Akiyama, Y., Muller, A., Wu, T. T., Montgomery, E. et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin. Cancer Res. 9, 2912-2919 (2003
24. Wei, S. H., Chen, C. M., Strathdee, G., Harnsomburana, J., Shyu, C. R., Rahmatpanah, F. et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8, 2246-2252 (2002
25. Kusano, M., Toyota, M., Suzuki, H., Akino, K., Aoki, F., Fujita, M. et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106, 1467-1479 (2006
26. Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010
27. Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012
28. Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M. et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009
29. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011
30. Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010
31. Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211 (2010
32. Cohn, S. L., Pearson, A. D., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M. et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J. Clin. Oncol. 27, 289-297 (2009
33. Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet. 33 (Suppl), 245-254 (2003
34. Li, E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3, 662-673 (2002
35. Abe, M., Ohira, M., Kaneda, A., Yagi, Y., Yamamoto, S., Kitano, Y. et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 65, 828-834 (2005
36. Abe, M., Westermann, F., Nakagawara, A., Takato, T., Schwab, M. & Ushijima, T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. 247, 253-258 (2007
37. Banelli, B., Brigati, C., Di Vinci, A., Casciano, I., Forlani, A., Borzi, L. et al. A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype. Lab. Invest. 92, 458-465 (2011
38. Kiss, N. B., Kogner, P., Johnsen, J. I., Martinsson, T., Larsson, C. & Geli, J. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. BMC Med. Genet. 13, 83 (2012
39. Schwab, M., Alitalo, K., Klempnauer, K. H., Varmus, H. E., Bishop, J. M., Gilbert, F. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305, 245-248 (1983
40. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121-1124 (1984
41. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313, 1111-1116 (1985
42. Grau, E., Martinez, F., Orellana, C., Canete, A., Yanez, Y., Oltra, S. et al. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol. Carcinog. 50, 153-162 (2011
43. Alaminos, M., Davalos, V., Ropero, S., Setien, F., Paz, M. F., Herranz, M. et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 65, 2565-2571 (2005
44. Alaminos, M., Davalos, V., Cheung, N. K., Gerald, W. L. & Esteller, M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J. Natl Cancer Inst. 96, 1208-1219 (2004
45. Misawa, A., Inoue, J., Sugino, Y., Hosoi, H., Sugimoto, T., Hosoda, F. et al. Methylation-Associated silencing of the nuclear receptor 1I2 gene in advanced-Type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res. 65, 10233-10242 (2005
46. Asada, K., Watanabe, N., Nakamura, Y., Ohira, M., Westermann, F., Scwab, M. et al. Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas. Jpn J. Clin. Oncol. in press (2013
47. Schulte, J. H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R. et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res. 69, 2065-2071 (2009
48. Ueda, R., Suzuki, T., Mino, K., Tsumoto, H., Nakagawa, H., Hasegawa, M. et al. Identification of cell-Active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 131, 17536-17537 (2009
49. George, R. E., Lahti, J. M., Adamson, P. C., Zhu, K., Finkelstein, D., Ingle, A. M. et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A Children's Oncology Group study. Pediatr. Blood Cancer 55, 629-638 (2010
50. Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793 (2006